- Status Complete
- Type New application
- Pre-PASC consultation -
- Pre-MSAC consultation -
- Outcome Supported
Application details
Reason for application
New non-MBS item.
Service or technology in this application
Tisagenlecleucel is an autologous, murine anti-CD19 chimeric antigen receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Type: Hybrid health technology
Medical condition this application addresses
Acute lymphoblastic leukaemia (ALL) is the malignant proliferation of lymphoid progenitor cells in the bone marrow.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin lymphoma (NHL).
Application documents
Application form
PICO confirmation
Public summary document
Public summary document
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Meetings to consider this application
- PASC meeting: 12 - 13 April 2018
- ESC meeting: 5 October 2018
- MSAC meeting:
- 22 - 23 November 2018
- 28 - 29 March 2019
- 9 April 2019